MGNX earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -3.91. Updated 2026-07-23.
MacroGenics (MGNX) Research Hub
MacroGenics (MGNX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 4 USD (-2.68%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.91, market cap 0.28B. This hub links to the full technical, earnings and options research available for MGNX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 4 USD (-2.68%) |
| 52-week range | 3.36 USD – 5.08 USD |
| Trend regime | Range |
| 14-day RSI | 48.8 (Neutral) |
| Trailing P/E | -3.91 |
| Market cap | 0.28B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for MGNX
Covered Call on MGNX: how it works, illustrative setup around the real 4 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on MGNX: how it works, illustrative setup around the real 4 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on MGNX: how it works, illustrative setup around the real 4 USD price, max profit/loss, breakeven and when to use it. Educational.
MGNX technical analysis: range, last 4 USD, RSI 48.8, 52w range 3.36 USD–5.08 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is MGNX in?
MacroGenics (MGNX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is MGNX in an uptrend or downtrend?
As of 2026-09-11, MGNX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is MGNX's trailing P/E ratio?
MGNX's trailing P/E is -3.91, with a market cap of 0.28B. See the earnings research page for full valuation detail.
When does MGNX next report earnings?
MGNX is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of 0.02583 USD.